Clinical Trials Arena on MSN1d
Immunovant will not seek approval for MG therapy, despite hitting endpointsThe company plans to use results from its Phase III myasthenia gravis study to support its pipeline candidate IMVT-1402 over ...
With what analysts are calling "strong" data, Amgen plans to file a regulatory submission for Uplizna, currently approved for ...
Zacks.com on MSN3d
AMGN Posts Upbeat Data on Uplizna From Myasthenia Gravis StudyNew late-stage study data shows that treatment with Amgen's Uplizna for a year improves disease symptoms in patients with ...
Amgen Inc (NASDAQ:AMGN) announced new data from the Phase 3 MINT trial of Uplizna (inebilizumab-cdon) for adult patients with ...
Zacks Investment Research on MSN2d
Amgen Rises Almost 22% YTD: Should You Buy, Hold or Sell the Stock?Amgen expects key drugs like Repatha, Evenity, Tezspire and oncology and rare disease drugs, as well as biosimilars to drive ...
Amgen has shared additional Phase 3 data for its rare disease drug Uplizna in myasthenia gravis, bolstering the company’s ...
Data from the Phase III MINT trial found that Uplizna demonstrated a greater reduction in Myasthenia Gravis Activities of ...
Amgen has shared new data from a late-stage trial of its B cell-depleting therapy Uplizna (inebilizumab-cdon) in adults with the rare autoimmune disorder generalised myasthenia gravis (gMG). The phase ...
New data from the phase 3 MINT trial in adults living with autoimmune disorder generalised myasthenia gravis (gMG) – which ...
Amgen (NasdaqGS:AMGN) has recently garnered attention due to promising Phase 3 MINT trial results for UPLIZNA in treating ...
Amgen AMGN reported the latest data from the phase III MINT study that evaluated the rare disease drug Uplizna (inebilizumab) for label expansion in generalized myasthenia gravis (gMG) indication.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback